Hyperion Therapeutics Report issue

Contributed to NME For profit Phase 3
Founded: South San Francisco CA United States (2006)
Status: Acquired by Horizon Pharma (2015)

Organization Overview

First Clinical Trial
2011
NCT01347073
First Marketed Drug
2013
glycerol phenylbutyrate (ravicti)
First NDA Approval
2013
glycerol phenylbutyrate (ravicti)
Last Known Activity
2013

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree